The Pharmacokinetics of the Last Mile: Protecting Cannabinoid Integrity in 2026
Source: IMAGE[/caption]
Editor's note: Cannabis and THCA/Hemp CBD products should have an active ingredient list on the container and a Certificate of Analysis (COA). Discuss your use of THC, cannabis, or CBD products with your health care provider. Dosing of cannabis products is variable, especially since they are not FDA regulated. Cannabis/CBD may interfere with other medications and should not be used in individuals with certain health conditions, including liver issues. CBD skin care products can be absorbed through the skin and have similar effects. Do not use cannabis products including edibles, drinks, and CBD if you are pregnant, nursing, or may become pregnant. Do not use cannabis products if driving or operating difficult or dangerous machinery. Children should not be exposed to cannabis or CBD products.
Whereas logistics professionals are more likely to concentrate on the purity and quality of laboratory extractions or cultivations, one of the most unstable parts of the medicinal substance's route to delivery — the final mile — may sometimes be neglected. The cannabis industry has turned to a pharmaceutical approach in 2026 to safeguard the chemical composition of the plant from exposure to damaging effects before reaching the end user.
Dr. Lazarus[/caption]
Philip Lazarus, PhD
Boeing Distinguished Professor, Pharmaceutical Sciences
Professor, Dept of Pharmaceutical Sciences
College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, WA 99210
MedicalResearch.com: What is the background for this study?
Response: Smoking and tobacco use remains a major health issue. Smokers use cigarette over the course of the day because the levels of nicotine, the addictive agent in cigarettes and other forms of tobacco, dimmish with time in the bloodstream due to the breakdown of nicotine by enzymes in the body. By inhibiting the breakdown of nicotine in smokers, one would expect that the levels of nicotine would remain higher after smoking a single cigarette, and that these individuals may not require lighting up another cigarette so quickly, reducing the number of cigarettes smoked over the course of a day. This could have a profound effect on reducing the overall harm incurred from smoking or from using other forms of tobacco.
In a single previous study, smokers who used a CBD inhaler exhibited a 40% reduction in cigarette use. In addition, while cannabis users are often smokers, previous studies have indicated that they smoke less cigarettes than non-cannabis-using cigarette smokers. In previous studies published in 2021, we found that major cannabinoids present in cannabis like THC and CBD inhibit major metabolizing enzymes in our body, including several that are important in drug metabolism. We hypothesized that CBD and its major active metabolite, 7-hydroxy (OH)-CBD, may also be inhibiting one or more of the enzymes important in the metabolism (or breakdown) of nicotine.

Dr. Rothbard[/caption]
MedicalResearch.com Interview with:
Jonathan Rothbard, MA, PhD
Steinman Lab Stanford Medicine
Co-founder